Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;6(6):932-6.
doi: 10.5114/aoms.2010.19304. Epub 2010 Dec 29.

Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?

Yemliha Yildiz  1 , Ilhan Yaylim-Eraltan, Soykan Arikan, H Arzu Ergen, Seden Küçücük, Turgay Isbir
Affiliations

Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?

Yemliha Yildiz et al. Arch Med Sci. 2010 Dec.

Abstract

Introduction: TNF-related apoptosis-inducing ligand (TRAIL) is a death ligand and also a member of the TNF superfamily. We aimed to investigate the possible relationship between TRAIL and breast cancer. Here, we report the results of the first association study on genetic variation in the TRAIL gene and its effect on breast cancer susceptibility and prognosis.

Material and methods: A C/T polymorphism at 1595 position in exon 5 of the TRAIL gene was genotyped in a Turkish breast cancer case-control population including 53 cases (mean age: 55.09 ±11.63 years) and 57 controls (mean age: 57.17 ±17.48 years) using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.

Results: There were no differences in the distribution of TRAIL genotypes and frequencies of the alleles in the breast cancer patients and controls. A heterozygous TRAIL CT polymorphism in exon 5 was present in 8.3% of tumour stage III-IV and 48.8% of stage I-II patients, and in 42.1% of controls. The reduced frequency of this genotype in patients who had advanced tumour stage was statistically significant (p = 0.017).

Conclusions: Our findings indicate that genetic variants of TRAIL at position 1595 in exon 5 might be associated with progression of breast cancer.

Keywords: TRAIL; breast cancer; polymorphism; prognosis; susceptibility.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Direct visualization of PCR-RFLP typing pattern of TRAIL genotypes by ethidium bromide staining. A 391-base pair TRAIL 1595 C/T fragment was amplified, cleaved with RsaI, and ele ctrophoresed on a 3% agarose gel. Results from seven representative breast cancer patients are shown. Lane 1: pUC19/Msp1 marker; lane 2: TT homozygote; lane 3, 4: CC homozygote; lane 5: CT heterozygotes; lane 6: CC homozygotes; lane 7: TT homozygotes; lane 8: CT heterozygotes
See this image and copyright information in PMC

References

    1. Otterbach F, Callies R, Frey UH, et al. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat. 2007;105:311–7. - PubMed
    1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153–64. - PubMed
    1. Zapata JM, Krajewska M, Krajewski S, et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors Breast Cancer Research and Treatment. 1998;47:129–40. - PubMed
    1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82. - PubMed
    1. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001;6:191–7. - PubMed